You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Select search scope: search across all journals or within the current journal

Search this journal

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

Copyright © 2026 by Sage Publications.京ICP备09090397号-11

Clin-Alert

Journal indexing and metrics

Journal Homepage Submission guidelines

Restricted access

Research article

First published online 2023-11

Reporting on Adverse Clinical Events

Volume 61, Issue 21-22

https://doi.org/10.1177/00694770231210450

Abstract

Keywords

Allopurinol (334)Baricitinib Tocilizumab (322)Certolizumab (320)Ciprofloxacin (331)COVID Vaccine (317 323 325)Dabigatran (326)Daunorubicin/Cytarabine Liposomal*(310)Dietary Supplement (333)Energy Drinks (316)Epirubicin (338)Goserelin*(313)Herbal Supplement (312)Human Papillomovirus Vaccine (328)Immune Checkpoint Inhibitor (319)Infigratinib (311)Isotretinoin (308)Ketamine (329)Medications (324 330 332 337)Methotrexate Biologics (315)Montelukast (314)Nirmatrelvir/Ritonavir (335)PDE-5 Inhibitors (318)Probiotics (309)Triclabendazole/Bithionol (321)Vaping (327)Vemurafenib Cobimetinib (336)

Get full access to this article

View all access options for this article.

Browse journal

Current issue OnlineFirst All issues

Similar articles

Retricted access

Reporting on Adverse Clinical Events

Retricted access

Recurrent and reversible bilateral palmar blue discoloration following administration of liposomal daunorubicin-cytarabine (Vyxeos®) for acute myeloid leukemia with myelodysplasia-related changes

Retricted access

Reporting on Adverse Clinical Events

Retricted access

Reporting on Adverse Clinical Events